Biotherapies (bio-drugs, Cellular Therapy and Gene Therapy) have a major impact on the treatment of different diseases.

Several applications concern regenerative medicine, due to the better knowledge in basic sciences, particularly in the domain of multipotent cells, from bone marrow, cord blood or from embryos. In oncology, anti-tumour immune therapy (adoptive, vaccinal or allogenic), and monoclonal antibodies represent therapeutic tools complementary to standard therapies.

The Center for Clinical Investigation (CIC for Biotherapy, CIC BT 509) from the university Hospital is a clinical research center for early trials (Phase 0, I, II), linked to fundamental and translational research. Its aim is to produce new scientific, medical and therapeutic knowledge, with respect of ethical and legal rules.

The CIC BT 509, situated in the department of Hematology-Oncology and the regional center of hematopoietic stem cell transplantation for adults and infants, include all the facilities to perform early clinical trials, from the concept to the realization and use of bio-molecules, cell- or gene-drugs.

The CIC BT 509 is present in the research regional network as well as the international one through the different institutes including the Institute of Research in Biotherapy located on the same site in the University Hospital of Montpellier. It has some partnership with industrial drug and device companies.

The CIC BT 509 is closely associated in “AXE” N°1 (malignant lymphopathies) and “AXE” 4 (Biotherapy) of the “Canceropole Grand Sud-Ouest (Limoges, Bordeaux, Toulouse, Montpellier, Nîmes). It coordinates the Haematology-Oncology network of the CIC in France and participates to the Montpellier-Heidelberg consortium in haematology, and opens new fields of collaborations in European and international networks.

The CIC BT 509 participates to a scientific and medical survey by diffusing informations to the different clinical departments which want to participate and develop new programs in Biotherapy.
**Partnership and collaborations**

**Internal to the University Hospital of Montpellier :**
- CIC pluri-thématique, with mutualization of the technical and scientific committee,
- Service of Haematology and Biotherapy, including the unity of Apheresé and Hémovigilance (UF n° 1467 and 1468),
- Unity of Cellular Therapy (person in charge Pr B Klein),
- Research institute in Biotherapy (IRB) and INSERM U847 (director Pr B Klein),
- Delegation in the clinical research,
- Poles Biology and pole Inner medicine, Dermatology, Haematology and Oncology of University Hospital of Montpellier
- Any services of University Hospital of Montpellier, realizing programs of clinical research in Biotherapy.

**Partnerships and regional collaborations :**
- Etablissements of regional care realizing programs of clinical research in Biotherapy,
- Montpellier Cancer.

**Partnerships and national collaborations :**
- Group co-workers (GOELAMS, GRAAL, GFM, Intergroups GOELAMS / LLC, IFM...),
- CRO (Contract Research Organisation).

**International partnerships :**
- Montpellier - Heidelberg consortium,
- European contract FP7: Weizman institute, Israel; university of Frankfurt, Germany, Institut Pasteur, France, University of Zurich, Swiss.
- Estimate with industrial drug and device companies.

**Transfer to the clinic and public health**

The CIC BT 509 participates to the innovative biotherapy, by facilitating translational research from academic institutes or from private partners, in the domain of early clinical trials. It is linked or develops all the tools for this type of research, from pre-clinical models to biological aspects.

In association with the Institute of research for Biotherapy, the CIC BT 509 proposes facilities to industrial companies in translational biology.

In association with the CIC network and cooperative groups, it participates to the creation of a research platform for early phases in order to compete with other well known centers for in the world.

The CIC BT 509 has an activity in public health focused in malignant lymphopathies, linked to cancer registry of Herault and other organisms.

**Valorisation**

The CIC BT 509, in contact with INSERM transfer and the DRC (Delegation in the Clinical Research) offers skills in the field of the valuation in clinical search(research) and translationnelle.

Immune therapy vacination by dendritic cells (patent N / REF.: 1H258820 0001 EP ECT / MLG / AGI), within the framework of hospital programs of clinical research (PHRC).

**Publications**


